drugset / Trial / NCT03926611
This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines
RandomizedParallel-groupTriple-blindTreatment
Summary
This was a multicenter, randomized, double-blind and placebo-controlled phase 2b dose-finding study to assess the efficacy and safety of LOU064 in adults chronic spontaneous urticaria (CSU) patients inadequately controlled by H1-antihistamines
Timeline
- Start
- 2019-06-06
- Primary completion
- 2021-01-14
- Completion
- 2021-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Remibrutinib | Small molecule | 10 mg | Oral |
| Subject | Remibrutinib | Small molecule | 25 mg | Oral |
| Subject | Remibrutinib | Small molecule | 35 mg | Oral |
| Subject | Remibrutinib | Small molecule | 100 mg | Oral |